Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Tissue Repair

Bronchogen

Khavinson bronchial bioregulator

Khavinson short peptide bioregulator

This Bronchogen entry draws on 3 cited sources published 2020 to 2021. The evidence available is graded Russian Research on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
Khavinson short peptide bioregulator
Drug class
Tissue Repair
Structure
Tetrapeptide Ala-Glu-Asp-Gly
Route
Oral
Half-life
Short (minutes)
Evidence tier
Russian Research
Availability
Research
Research depth
10 indexed citations (PubMed 7 · CT 0 · EPMC 3) →

Mechanism of action

DNA-binding peptide; modulates tissue-specific gene expression in bronchial epithelium

Reported areas of research

Bronchial epithelial support; respiratory mucosal repair in aged models

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

Oral capsule 1-2x daily per Khavinson protocol

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Limited clinical evidence; Russian-origin data only

Compared with

Bronchogen has published head-to-head comparisons with 16 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Bronchogen in research literature?

Published peptide research reports the following dosing approach for Bronchogen: Oral capsule 1-2x daily per Khavinson protocol. This is a research reference, not a clinical recommendation.

How is Bronchogen administered in research?

Bronchogen is administered via the following routes in published studies: Oral.

What is the reported half-life of Bronchogen?

No measured half-life for Bronchogen is reported in the literature catalogued here. The catalog describes it as: Short (minutes).

Is Bronchogen FDA-approved?

No. Bronchogen is not an FDA-approved drug. PeptideHelper.org catalog status: Research.

What level of evidence supports Bronchogen?

The current evidence base for Bronchogen is best characterised as: Russian Research. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Bronchogen?

Known concerns reported in the literature for Bronchogen include: Limited clinical evidence; Russian-origin data only. Always consult a qualified clinician before any human use.

Is there anyone who should not use Bronchogen?

No formal contraindications are established for Bronchogen, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited clinical evidence; Russian-origin data only. Always consult a qualified clinician before any human use.

How does Bronchogen work?

The mechanism of action reported for Bronchogen in the literature: DNA-binding peptide; modulates tissue-specific gene expression in bronchial epithelium.

What is Bronchogen studied for?

Bronchogen has been studied in the published literature for: Bronchial epithelial support; respiratory mucosal repair in aged models. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Bronchogen?

Bronchogen is classified as: Khavinson short peptide bioregulator. Also known as: Khavinson bronchial bioregulator.

Drug class

Research focus area

All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.

Primary sources

  1. Khavinson VK et al. Peptide regulation of gene expression — a systematic review. Molecules 2021. PMID 34834147
  2. Khavinson V et al. Peptide regulation of cell differentiation. Stem Cell Rev Rep 2020. PMID 31808038
  3. Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…